Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau ; day:05 ; month:05 ; year:2021 ; extent:11
EMBO molecular medicine / European Molecular Biology Organization ; (05.05.2021) (gesamt 11)

Creator: Mattsson-Carlgren, Niklas
Janelidze, Shorena
Bateman, Randall J.
Smith, Ruben
Stomrud, Erik
Serrano, Geidy E.
Reiman, Eric M.
Palmqvist, Sebastian
Dage, Jeffrey L.
Beach, Thomas G.
Hansson, Oskar

DOI: 10.15252/emmm.202114022

URN: urn:nbn:de:101:1-2021050515214224130972

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:50 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Mattsson-Carlgren, Niklas
Janelidze, Shorena
Bateman, Randall J.
Smith, Ruben
Stomrud, Erik
Serrano, Geidy E.
Reiman, Eric M.
Palmqvist, Sebastian
Dage, Jeffrey L.
Beach, Thomas G.
Hansson, Oskar

Other Objects (12)

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

Towards a unified protocol for handling of CSF before β-amyloid measurements

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Relationship between amyloid and tau levels and its impact on tau spreading

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Local structural preferences in shaping tau amyloid polymorphism

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

Towards a unified protocol for handling of CSF before β-amyloid measurements

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Relationship between amyloid and tau levels and its impact on tau spreading

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Local structural preferences in shaping tau amyloid polymorphism

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

Towards a unified protocol for handling of CSF before β-amyloid measurements

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Relationship between amyloid and tau levels and its impact on tau spreading

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Local structural preferences in shaping tau amyloid polymorphism

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

Towards a unified protocol for handling of CSF before β-amyloid measurements

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Relationship between amyloid and tau levels and its impact on tau spreading

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Local structural preferences in shaping tau amyloid polymorphism

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

Towards a unified protocol for handling of CSF before β-amyloid measurements

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Relationship between amyloid and tau levels and its impact on tau spreading

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Local structural preferences in shaping tau amyloid polymorphism

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

Towards a unified protocol for handling of CSF before β-amyloid measurements

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Relationship between amyloid and tau levels and its impact on tau spreading

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Local structural preferences in shaping tau amyloid polymorphism

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Related objects

Reset password